Table 2.
Clinical stem cell treatments for chronic wounds.
| Year | Reference | Study design (number of participants) | Stem cell source and modality of treatment | Result |
|---|---|---|---|---|
| 2003 | 109 | Case report, proof-of-principle (n = 3) | Bone marrow cells applied topically in isotonic NaCl solution | Complete healing of previously recalcitrant ulcer in 3/3 participants |
| 2005 | 110 | Case report (n = 1) | Bone marrow cells applied topically in isotonic NaCl solution | Improvement in epithelization and vascularization within 1 week |
| 2007 | 111 | Case report, experimental treatment (n = 8) | Cultured MSCs delivered in collagen sponge artificial dermis | Complete healing of previously recalcitrant ulcer in 8/8 participants |
| 2008 | 113 | Case report, experimental treatment (n = 20) | Cultured MSCs delivered in fibrin spray | Improvement of ulcer in 18/20 patients, healing positively correlated with number of cells applied |
| 2009 | 117 | Randomized control trial (n = 35) | Cultured ASCs in fibrin glue | Perianal fistula healed in 17/24 patients in treatment group, 4/25 in control |
| 2009 | 119 | Randomized control trial (n = 24) | Cultured BMMSCs | Significant improvements in ulcer size in experimental group |
| 2010 | 118 | Randomized control trial (n = 96) | Concentrated BMMSCs applied directly to wound bed | Significantly decreased limb amputations among patients in treatment group at 90 days post treatment |
| 2011 | 116 | Case report, experimental treatment (n = 22) | BM-MNCs suspended in saline solution injected into “wound pocket” | 19/22 pressure ulcers healed in 21 days, no recurrence in 19 months follow-up |
| 2012 | 114 | Case report, experimental treatment (n = 15) | ASCs injected intramuscularly | Improved vascularity and pain in ischemic ulcers at 6 months follow up |
| 2014 | 115 | Case report, experimental treatment (n = 3) | CD34 + BMCs injected into wound bed | Improvement in wound size in 3/3 patients |
| 2015 | 121 | Phase 2 randomized clinical trial (n = 25) | ASCs applied topically to wound | Results not yet published |
| 2016 | 120 | Phase 2 randomized clinical trial (n = 97) | Bone marrow aspirate injected into ischemic tissue | Results not yet published |
| 2018 | 157 | Case report, proof of principle (n = 3) | Early passage MSCs applied topically | Significantly improved healing within 1 week of application in 3/3 participants |
| 2018 | 122 | Phase 1 safety trial (n = 20) | Allogeneic stem cells topically added to burns | Study still ongoing |